These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 29313569)

  • 1. Fosfomycin: A Revisited Antibiotic for Urinary Tract Infections.
    Parikh FS
    J Assoc Physicians India; 2017 Sep; 65(9):11. PubMed ID: 29313569
    [No Abstract]   [Full Text] [Related]  

  • 2. [Our experience in the use of fosfomycin in human therapy].
    De Rosa F; Pauselli A; Matocci G; Petrucci G
    Minerva Med; 1978 Dec; 69(59):4115-8. PubMed ID: 105328
    [No Abstract]   [Full Text] [Related]  

  • 3. [Indications and limits in the use of fosfomycin in urology. Preliminary notes].
    Meazza A; Marzorati G
    Minerva Med; 1978 Dec; 69(59):4107-9. PubMed ID: 740307
    [No Abstract]   [Full Text] [Related]  

  • 4. [Clinical experience with fosfomycin in urinary tract infections (author's transl)].
    Peters HJ; Eicher R
    MMW Munch Med Wochenschr; 1981 May; 123(18):748-50. PubMed ID: 6785627
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fosfomycin in treatment of chronic urinary tract infection.
    Gobernado M; Oleza J; Santos M; Roman J; Paz M; Mascaros E; Almela J
    Chemotherapy; 1975; 21(2):99-107. PubMed ID: 1157571
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activity of Fosfomycin against Extended-Spectrum-β-Lactamase-Producing Uropathogens in Patients in the Community and Hospitalized Patients.
    Linsenmeyer K; Strymish J; Weir S; Berg G; Brecher S; Gupta K
    Antimicrob Agents Chemother; 2016 Feb; 60(2):1134-6. PubMed ID: 26596940
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oral and intravenous fosfomycin in complicated urinary tract infections.
    López-Montesinos I; Horcajada JP
    Rev Esp Quimioter; 2019 May; 32 Suppl 1(Suppl 1):37-44. PubMed ID: 31131591
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fosfomycin for UTIs.
    Drug Ther Bull; 2016 Oct; 54(10):114-117. PubMed ID: 27737907
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of MDR urinary tract infections with oral fosfomycin: a retrospective analysis.
    Seroy JT; Grim SA; Reid GE; Wellington T; Clark NM
    J Antimicrob Chemother; 2016 Sep; 71(9):2563-8. PubMed ID: 27246234
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fosfomycin for Treatment of Prostatitis: New Tricks for Old Dogs.
    Grayson ML; Macesic N; Trevillyan J; Ellis AG; Zeglinski PT; Hewitt NH; Gardiner BJ; Frauman AG
    Clin Infect Dis; 2015 Oct; 61(7):1141-3. PubMed ID: 26063723
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ZTI-01 (fosfomycin for injection) in the treatment of hospitalized patients with complicated urinary tract infections.
    Burgos RM; Rodvold KA
    Future Microbiol; 2019 Apr; 14():461-475. PubMed ID: 30854892
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacodynamic Evaluation of Fosfomycin against Escherichia coli and Klebsiella spp. from Urinary Tract Infections and the Influence of pH on Fosfomycin Activities.
    Fedrigo NH; Mazucheli J; Albiero J; Shinohara DR; Lodi FG; Machado ACDS; Sy SKB; Tognim MCB
    Antimicrob Agents Chemother; 2017 Aug; 61(8):. PubMed ID: 28607025
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The role of fosfomycin in the management of urinary tract infections].
    Zaitsev AV; Kolontarev KB
    Urologiia; 2017 Sep; (4):91-96. PubMed ID: 28952700
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fosfomycin for treatment of multidrug-resistant pathogens causing urinary tract infection: A real-world perspective and review of the literature.
    Babiker A; Clarke L; Doi Y; Shields RK
    Diagn Microbiol Infect Dis; 2019 Nov; 95(3):114856. PubMed ID: 31307867
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An update on the management of urinary tract infections in the era of antimicrobial resistance.
    Bader MS; Loeb M; Brooks AA
    Postgrad Med; 2017 Mar; 129(2):242-258. PubMed ID: 27712137
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Potential role of fosfomycin in the treatment of community-acquired lower urinary tract infections caused by extended-spectrum β-lactamase-producing Escherichia coli.
    Wilson DT; May DB
    Am J Ther; 2013; 20(6):685-90. PubMed ID: 21768870
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fosfomycin as a salvage therapy for treating urinary tract infections due to multidrug-resistant Escherichia coli.
    Nordmann P; Sadek M; Poirel L; Chakraborty T
    Eur J Clin Microbiol Infect Dis; 2022 Apr; 41(4):689-690. PubMed ID: 35118568
    [No Abstract]   [Full Text] [Related]  

  • 18. [Not Available].
    Dinh A; Bouchand F; Salomon J; Bruyère F
    Rev Prat; 2016 Jun; 66(6 Suppl):e255-64. PubMed ID: 27538335
    [No Abstract]   [Full Text] [Related]  

  • 19. [Uncomplicated urinary tract infections, what about fosfomycin and nitrofurantoin in 2006?].
    Honderlick P; Cahen P; Gravisse J; Vignon D
    Pathol Biol (Paris); 2006; 54(8-9):462-6. PubMed ID: 17027182
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of recurrent complicated urinary tract infections in children with vesicoureteral reflux.
    Wu TH; Huang FL; Fu LS; Chou CM; Chien YL; Huang CM; Lin CF; Chen PY
    J Microbiol Immunol Infect; 2016 Oct; 49(5):717-722. PubMed ID: 25442872
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.